175 related articles for article (PubMed ID: 23547867)
1. The current status and future impact of targeted therapies in non-Hodgkin lymphoma.
Ujjani C; Cheson BD
Expert Rev Hematol; 2013 Apr; 6(2):191-202; quiz 203. PubMed ID: 23547867
[TBL] [Abstract][Full Text] [Related]
2. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
4. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibody therapy for malignant lymphoma].
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Med Klin (Munich); 2005 Jan; 100(1):14-24. PubMed ID: 15654538
[TBL] [Abstract][Full Text] [Related]
6. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
LaCasce AS; Freedman AS
Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
[TBL] [Abstract][Full Text] [Related]
7. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
[TBL] [Abstract][Full Text] [Related]
9. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
10. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.
Micallef IN; Kirk A; Norton A; Foran JM; Rohatiner AZ; Lister TA
Blood; 1999 Apr; 93(7):2427-8. PubMed ID: 10215354
[No Abstract] [Full Text] [Related]
11. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
Safdari Y; Ahmadzadeh V; Farajnia S
Invest New Drugs; 2016 Aug; 34(4):497-512. PubMed ID: 27075017
[TBL] [Abstract][Full Text] [Related]
12. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
13. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
14. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
Herrera AF
Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
[TBL] [Abstract][Full Text] [Related]
15. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
16. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
Derby L; Czuczman MS
Future Oncol; 2011 Aug; 7(8):963-79. PubMed ID: 21823892
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
Feuring-Buske M; Buske C; Unterhalt M; Hiddemann W
Ann Hematol; 2000 Apr; 79(4):167-74. PubMed ID: 10834503
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment approaches and novel therapies for lymphoma.
Leonard JP; Friedberg JW; Hagemeister FB; Levine AM
Clin Adv Hematol Oncol; 2007 Aug; 5(8 Suppl 12):4-20; quiz 1 p following 20. PubMed ID: 18154235
[No Abstract] [Full Text] [Related]
20. [Treatment options in non-Hodgkin lymphomas].
Tilly H
Rev Prat; 2010 Jan; 60(1):69-74. PubMed ID: 20222315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]